ClinicalTrials.gg
CompletedNCT05275465Updated Apr 7, 2023

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

A Phase 1 interventional study of HH-006 and Placebo in Hepatitis B, sponsored by Huahui Health. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-07.

Sponsored by Huahui Health · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Hepatitis B with a site in Australia — 6 open to participants now, 9 under way, none of them phase 3. Hepatitis B · Australia.

Enrollment
39th of 42
33 · median 103
Started
2022
with 5 others
Phase 1
12 of 50
2 open now
Registered
41st of 50
by date

Among the 50 studies in Hepatitis B with a site in Australia, this one is the 39th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2022, is one of 12 in phase 1, and was the 41st registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

6 of the 50 studies in Hepatitis B with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Hepatitis B with a site in Australia, or all of them as a file.
02

Study summary

Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing monoclonal antibody in healthy volunteers, and to determine its pharmacokinetic profile and immunogenicity.

Read the detailed description

This is a double-blind, placebo-controlled, Phase Ia study aimed to evaluate the safety and tolerability of HH-006 after single ascending doses given as subcutaneous injections.

03

Conditions studied

  • Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy male or female individuals aged between 18 to 65 years old
  • A bodyweight ≥ 45 kg and the (BMI) is between 18 to 32 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • History of anaphylaxis or other significant allergy in the opinion of the Investigator or known allergy or to any of the components of the IP
  • History of drug, alcohol, or substance abuse
  • Any history of liver disease or known hepatic, or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Any history of anaphylaxis, severe allergic reaction, neutralizing antibody generations, or hypersensitivity to albumin or any protein-based therapeutics such as natalizumab (Tysabri) or any other monoclonal antibodies
  • Any previous exposure to chimeric, humanized, or human monoclonal antibody, whether licensed or not
  • Medical history of active infection (acute or chronic)
  • Any safety concern or personal condition that is inappropriate for the study participation per the Investigator's judgement.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    HH-006

    Drug: HH-006

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugHH-006

    Different dose levels of HH-006

  • DrugPlacebo

    Different dose levels of placebo

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment emergent adverse events (TEAEs)

    An AE that started on or after the first study treatment or that worsened after the first study treatment will be regarded as TEAEs.

    Time frame: Day 1- Day 113

  2. Severity of treatment emergent adverse events as measured by CTCAE v 5.0

    Time frame: Day 1- Day 113

  3. Duration of treatment emergent adverse events

    Time frame: Day 1- Day 113

Secondary outcomes

  1. Cmax

    Maximum observed HH-006 concentration

    Time frame: Day 1-Day 113

  2. Tmax

    Time to maximum observed HH-006 concentration

    Time frame: Day 1-Day 113

  3. AUC0- last

    Area under the plasma concentration-time curve from time zero to the last time point with measurable concentration

    Time frame: Day 1-Day 113

  4. AUC0-inf

    AUC from time zero extrapolated to infinity

    Time frame: Day 1- Day 113

  5. t1/2

    Apparent terminal half-life

    Time frame: Day 1- Day 113

  6. CL (SAD)

    Apparent total body clearance

    Time frame: Day 1-Day 113

  7. CL/F (SAD)

    Apparent clearance

    Time frame: Day 1-Day 113

  8. Vz/F (SAD)

    Apparent terminal volume of distribution

    Time frame: Day 1-Day 113

  9. Titres of anti drug antibodies (ADA) to HH-006

    To determine the immunogenicity of HH-006

    Time frame: Day 1- Day 113

07

Study locations

1 site
  • Q-Pharm Pty Ltd (Nucleus Network Pty Ltd)
    Brisbane, Queensland 4006, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Dec 2022, 7 months.

Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 7 months is below that.

Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2022
First posted
Mar 11, 2022
StartActual
May 3, 2022
Primary completionActual
Dec 29, 2022
CompletionActual
Dec 29, 2022
Last update
Apr 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05275465
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Mar 11, 2022
Start date
May 3, 2022
Primary completion
Dec 29, 2022
Completion
Dec 29, 2022
Last update
Apr 7, 2023

Study contacts

Jason Lickliter
principal investigator · Nucleus Network

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HH-006

Start the discussion